Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

Abstract The SARS-CoV-2 pandemic has disrupted clinical trials worldwide. The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) has tracked clinical trial disruption by surveying its 58 trial sites across 17 European countries and collated information on measures to mitigate the im...

Full description

Bibliographic Details
Main Authors: Silke van Koningsbruggen-Rietschel, Fiona Dunlevy, Veerle Bulteel, Kate Hayes, Anne Verbrugge, Hettie M. Janssens, Nadine Dufeu, Nicholas J. Simmonds, Lieven J. Dupont, Damian G. Downey
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Trials
Subjects:
Pandemic
Mitigation
SARS-CoV-2
COVID-19
Clinical trials
Cystic fibrosis
Online Access:https://doi.org/10.1186/s13063-021-05457-5

Internet

https://doi.org/10.1186/s13063-021-05457-5

Similar Items